Roivant Sciences
https://roivant.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Roivant Sciences
Ensho Joins Race To Develop An Oral Integrin Inhibitor For IBD
Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.
Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments
Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Sumitomo Pharma To Cut 400 US Employees Amid Latuda LOE
After reducing 500 employees last year while reorganizing its subsidiaries in the US in the aftermath of patent expiration for its mainstay product Latuda, the Japanese firm has decided to move ahead with another rationalization affecting 400 employees there.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Altavant Sciences
- Alyvant
- Aruvant Sciences
- Axovant Sciences
- Cyotvant Sciences
- Datavant
- Dermavant Sciences
- Enzyvant
- Genevant
- Immunovant Sciences
- Metavant Sciences
- PhaseRx
- Respivant
- Roivant Health
- Roivant Neurosciences Ltd
- Roivant Pharma
- Roivant Sciences Ltd.
- Inc.
- Sinovant Sciences
- Sumitovant Biopharma Ltd.
- Valor Biotechnology
- Axovant Gene Therapies Ltd.
- Kinevant Sciences
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice